Klin Farmakol Farm. 2014;28(1):23-25

Pharmaco-economics of biological treatment; focus on biosimilars

Jana Skoupá
Medicínské datové centrum, 1. LF UK Praha

The article describes the history of biosimilar products and current status. Biosimilars represent a group of biological products with comparable

efficacy and safety to the reference substance, although it is not appropriate to call them “generics“. Health-economic analyses

in biosimilars usually apply cost-minimization, which strictly requires equal efficacy and safety of the assessed substance and comparator.

Available literature shows, that biosimilarsare cost-saving, the estimated potential of savings is currently in the range of 15–30 %.

Keywords: biosimilars, health-economy, costs, cost-effectiveness, cost-minimization analysis

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skoupá J. Pharmaco-economics of biological treatment; focus on biosimilars. Klin Farmakol Farm. 2014;28(1):23-25.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rickwood S, Di Biase S. Searching for Terra Firma in the Biosimilars and Non-Original Biologics Market. Insight for the Comming Decade of Change. IMS Health Biosimilars and Non-Original Biologics. Dostupné na www.ims.com.
    2. Rovira J, Espin J, García L, et al. Impact of Biosimilars´entry in the EU Market; 2011. Dostupné na www.ec.europa.eu.
    3. Inflectra: EPAR - Public Assessment Report 4.10.2013. Dostupné na www.emea.europa.eu.
    4. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J 2002; 43 (4): 462-469. Go to PubMed...
    5. Mellstedt H. The future of biosimilars. Hosp Pharm Europe 2010; 49: 33-34.
    6. Long M, Trout J, et al. Biosimilars: HGH to TNFS, how will payers respond? Proce Spective 2009. Go to original source...
    7. Zuniga L, Calvo B. Biosimilars - the way forward. Hosp Pharm Europe 2010; 50: 33-34.
    8. Dodávky léčivých přípravků v ČR. Dostupné na www.sukl.cz.
    9. Scottish Medicines Consortium: Epoetin Zeta. Dostupné na www.scottishmedicines.org.uk.
    10. Aapro M, Cornes P, Abraman I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Practice 2012; 18 (2): 171-179. Go to original source... Go to PubMed...
    11. Naemi A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 2013; 13: 11. Go to original source... Go to PubMed...
    12. Haustein R, de Millas C, Höer A, Häussler B. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012; 1 (3-4): 120-126. Go to original source...
    13. Orlewska E, Ancuta I, Anic B, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011; 17 (4): SR1-13. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.